Open AccessEfficacy of Etanercept in the Treatment of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
Author(s) -
Sean Dreyer
Publication year - 2021
Publication title -
cutis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.289
H-Index - 53
eISSN - 2326-6929
pISSN - 0011-4162
DOI - 10.12788/cutis.0288
Subject(s) - medicine , toxic epidermal necrolysis , etanercept , dermatology , immunology , tumor necrosis factor alpha
It has been suggested that the use of etanercept for treatment of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) might provide improved mortality benefit and decreased skin healing times. This retrospective study compared the use of single-dose subcutaneous etanercept to intravenous immunoglobulin (IVIG) and supportive care alone. Thirteen patients were treated with a single dose (50 mg) of subcutaneous etanercept. Results of this study support the use of etanercept as a potentially beneficial agent in the treatment of SJS/TEN.